Literature DB >> 17241711

A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice.

J E Quarry1, K E Isherwood, S L Michell, H Diaper, R W Titball, P C F Oyston.   

Abstract

Francisella tularensis subspecies novicida mutants have been made with deletions introduced into the purA or purF genes. These mutants demonstrated the expected growth requirement for purines and complementation with the wild type genes restored the ability to grow on purine deficient media. The mutants were at least 10,000-fold attenuated by the ip challenge route in Balb/C mice and defective for survival in J774A.1 mouse macrophages. Immunisation with the purA mutant did not provide protection against a subsequent challenge with 100 median lethal doses of F. tularensis subspecies novicida. Immunisation of mice with the purF mutant provided protection against a subsequent challenge with F. tularensis subspecies novicida but not against a subspecies tularensis challenge. These findings suggest that purine auxotrophs of F. tularensis should be further evaluated as live attenuated vaccines against tularemia, but that differential effects are seen depending on which step in the biosynthetic pathway is inactivated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17241711     DOI: 10.1016/j.vaccine.2006.11.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Glycosylation of DsbA in Francisella tularensis subsp. tularensis.

Authors:  Rebecca M Thomas; Susan M Twine; Kelly M Fulton; Luc Tessier; Sara L N Kilmury; Wen Ding; Nicholas Harmer; Stephen L Michell; Petra C F Oyston; Richard W Titball; Joann L Prior
Journal:  J Bacteriol       Date:  2011-07-29       Impact factor: 3.490

2.  Genome-wide screen in Francisella novicida for genes required for pulmonary and systemic infection in mice.

Authors:  Petra S Kraemer; Allison Mitchell; Mark R Pelletier; Larry A Gallagher; Mike Wasnick; Laurence Rohmer; Mitchell J Brittnacher; Colin Manoil; Shawn J Skerett; Nina R Salama
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

Review 3.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

4.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

Review 5.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

6.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

7.  RipA, a cytoplasmic membrane protein conserved among Francisella species, is required for intracellular survival.

Authors:  James R Fuller; Robin R Craven; Joshua D Hall; Todd M Kijek; Sharon Taft-Benz; Thomas H Kawula
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

Review 8.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

Review 9.  Rationally designed tularemia vaccines.

Authors:  Barbara J Mann; Nicole M Ark
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

10.  Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.

Authors:  Qingmei Jia; Bai-Yu Lee; Daniel L Clemens; Richard A Bowen; Marcus A Horwitz
Journal:  Vaccine       Date:  2009-01-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.